Not as expected..but as pharmacy/ healtcare play is still there....the price will be coming up again. Look at HLT, Esceram, and many more counter with big loss ....sharp down only temporary....few day later...swing up again
GETS ..more bad result.. loss 15.5 mil.....but still in play today...until limit up...maybe Tuesday continue to climb higher....I confident insider already know this result.....and this..had been price in...
AGES....show surprise result at midday.....but no effect today......so conclusion? Market is always rotational play with yr 2020 theme..rubber gloves, healtcare,pharmacy, technology, furniture, food
Ya market is ready to price in (Gap down & go up)........MCO had negative effect for all counter in Bursa.....so this is not company factor.....this is MCO factor......during this pandemic Covid19....business in healtcare/farmacy more needed as more people concern about health
Next month onwards most stocks will likely fare better as many corporate results seems to be in the negative position due to the pandemic Covid19 disease and with the restrictions order imposed that affected business activities
Latest Prospects segment from Biohldg report. This is surely a stock to invest for long term gain.
As we move forward, the Group remains focused on conserving cash while strengthening our business segments. For the domestic manufacturing business, the Group continues its efforts to build a solid product pipeline, especially on immunity-related offerings, to cater to the demands of our existing ODM clients, while securing new customers. At the same time, Bioalpha aims to fill the existing supply shortage of imported health supplements products in Malaysia due to trade disruptions arising from the lockdown measures.
As for our export business, in view of the current development, the Group anticipates export sales to gradually recover in the last quarter of 2020, following trade activities normalization and gradual easing of government containment measures. Specifically in China, the Group continues to work closely with distributors and partners there. Meanwhile, the newly-secured contract to supply health food and nutritional meals to the public and private sectors in China is expected to accelerate the Group’s growth there, opening a new income stream and market segment. Progress in Indonesia, on the other hand, had been muted due to slower-thanexpected regulatory approvals for the health supplement products. The Group foresees revenue from Indonesia to pick up as and when more approvals are secured moving forward. Overall, we expect our manufacturing business to pick up in the second (2nd) half of 2020, in tandem with the increase in healthcare awareness and year-end promotional campaigns.
On the retail pharmacy business, our efforts are channelled on improving customer services at the Constant outlets, while intensifying the Group’s promotional and marketing initiatives. We believe the increased foot traffic would sustain as people prefer to visit community pharmacies such as Constant instead of those at the malls to avoid crowd in the present pandemic situation. We are also working towards enhancing our online presence to increase customer reach, leveraging on the greater adoption of e-commerce amongst consumers due to COVID-19 pandemic.
On balance, in view of the COVID-19 outbreak, the Group faces various challenges in the coming financial year ending 31 December 2020, and overall results performance would be lower than the previous year. Nevertheless, we are confident of navigating through these headwinds, supported by our ongoing initiatives, solid financial position and extensive experience of 15 years in the health supplement industry.
Today the heavy selldown on index link stocks is due to institutional funds portfolios restructuring and rebalancing for the 2nd quarter position amid with the inclusion of supermax and kossan into the klci constituents stock . Looking forward for improvement in the 3rd quarter corporate results to fare better than the 2nd qr . Looking ahead of next week klci performance .
Looking at the current scenario , even lost making company can limit up and hence therefore lost making company would have limited downside risks . There are many companies currently in the 2nd quarter posing heavy financial losses but price rebounded back one or 2 days afterwards not like in the past years . Should buy on weakness with its back up plan with China in relation with its 2.1 billions health related products agreement
Market is just about most people play in that counter cause of sentiment/theme/interest. It's doesn't always must correlate at company performance result. Why most counter like Esceram, Biohlg, and some other counter show excellent performance/ quater result last year ....(more better than this year)....but last year share price very low (around 0.10 sen)....Even this year ..everybody know ..the conditions very bad...MCO, Covid19, more bankruptcy etc...but overallmarket performance very very excellent...the best since 2000 (dot com rally)
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: Building management systems (BMS), solar thermal systems and energy-saving services provider, Solar District Cooling Bhd aims to list on the Ace Market!
MQ Trader 576 views | 3 d ago
0:17
New IPO: The onshore and offshore support services provider for the O&G industry, Steel Hawk Bhd aims to list on the Ace Market!
MQ Trader 13059 views | 11 d ago
0:17
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
HamsterHuat
2,852 posts
Posted by HamsterHuat > 2020-08-28 17:23 | Report Abuse
oklah...@smkts123......follow your lead..
have buy in BioAlpha below 30cents..
Let wait for good news